Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04838301 · ClinicalTrials.gov registry record · Phase 2
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
A Phase 2 study of Neurodegenerative Diseases and Alzheimer Dementia, sponsored by University of Arizona.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 10
- Study locations
NCT04838301: Recruiting Phase 2 study of Neurodegenerative Diseases and Alzheimer Dementia, sponsored by University of Arizona.
NCT04838301 is a Phase 2 study of Neurodegenerative Diseases and Alzheimer Dementia that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 100 participants, below the 168,526-participant average among 12 other Neurodegenerative Diseases trials with a reported enrollment target (100% lower). The trial reports 10 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04838301, a Phase 2 study of Neurodegenerative Diseases and Alzheimer Dementia, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 10
- Study locations
Study Summary
A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
Primary Outcome
mm3
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Allopregnanolone
Study Locations (10)
Florida
- Optimus U Corporation - Miami
- Miami Jewish Health - Miami
- Combined Research Orlando - Orlando
- Conquest Research - Winter Park
California
- ATP Clinical Research - Costa Mesa
- Wake Research-PRI, LLC - Los Alamitos
- Syrentis Clinical Research - Santa Ana
Arizona
- Perseverance Research Center - Scottsdale
- University of Arizona / Clinical & Translational Sciences Research Center - Tucson
Massachusetts
- MedVadis Research - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-08-15 |
| Est. Completion | 2027-03-18 |
| Phase | Phase 2 |
What NCT04838301 shows while recruiting
NCT04838301 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 168,526-participant average among 12 other Neurodegenerative Diseases trials with a reported enrollment target (100% lower).
The record links to 3 conditions, with Neurodegenerative Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04838301 lists 10 locations in 4 states (Florida, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT04838301 about?
NCT04838301 is a clinical study titled "Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease". A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
What is the current status of trial NCT04838301?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-08-15. Estimated completion is 2027-03-18.
What conditions does trial NCT04838301 study?
This clinical trial studies the following conditions: Neurodegenerative Diseases, Alzheimer Dementia, Late Onset Alzheimer Disease.
What interventions are being tested in trial NCT04838301?
The interventions under investigation include: Placebo (OTHER), Allopregnanolone (DRUG).
Who is sponsoring clinical trial NCT04838301?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04838301 being conducted?
This trial has 10 study locations across Arizona, California, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurodegenerative Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04838301's enrollment target sits among peer trials
100 7th of 12 higher than 6 of 12 other Neurodegenerative Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurodegenerative Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AMX0035 and Progressive Supranuclear Palsy
ACTIVE NOT RECRUITING · Phase 2
-
Neurologic Stem Cell Treatment Study
RECRUITING · NA
-
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
RECRUITING
-
Home Exercise for Individuals with Neurodegenerative Disease
RECRUITING · NA
-
Observational Pharmaco-Epidemiology Research & Analysis
RECRUITING
-
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI